Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Allergen immunotherapy for allergic asthma : The future seems bright

Diamant, Zuzana LU ; van Maaren, Maurits ; Muraro, Antonella ; Jesenak, Milos and Striz, Ilja (2023) In Respiratory Medicine 210.
Abstract

Allergen specific immunotherapy (AIT) is the only causal therapeutic option for allergic airway diseases including asthma and allergic rhinitis. AIT has been shown to restore the allergen immune tolerance, can modify both the early and late-onset allergen-specific airway hyperreactivity, helps to achieve disease control/remission and prevents new sensitisations. Recent real life data on long-term effectiveness of house dust mite (HDM) AIT in a large group of patients with HDM-driven asthma further underscored its unique therapeutic potential as well as confirmed previous data with pollen AIT. More widespread use of this causal treatment in select patient populations should further move this promising therapeutic field. In this... (More)

Allergen specific immunotherapy (AIT) is the only causal therapeutic option for allergic airway diseases including asthma and allergic rhinitis. AIT has been shown to restore the allergen immune tolerance, can modify both the early and late-onset allergen-specific airway hyperreactivity, helps to achieve disease control/remission and prevents new sensitisations. Recent real life data on long-term effectiveness of house dust mite (HDM) AIT in a large group of patients with HDM-driven asthma further underscored its unique therapeutic potential as well as confirmed previous data with pollen AIT. More widespread use of this causal treatment in select patient populations should further move this promising therapeutic field. In this mini-review, we discuss updates on new insights based on real world patient data.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Allergen immunotherapy, Asthma, Clinical effectiveness, Disease modification, Disease remission, Mechanisms, Prevention
in
Respiratory Medicine
volume
210
article number
107125
publisher
Elsevier
external identifiers
  • scopus:85149805928
  • pmid:36702170
ISSN
0954-6111
DOI
10.1016/j.rmed.2023.107125
language
English
LU publication?
yes
id
1cd0587b-ce7b-4b91-a786-062d2ca21d63
date added to LUP
2023-04-24 13:56:21
date last changed
2024-06-15 02:10:03
@article{1cd0587b-ce7b-4b91-a786-062d2ca21d63,
  abstract     = {{<p>Allergen specific immunotherapy (AIT) is the only causal therapeutic option for allergic airway diseases including asthma and allergic rhinitis. AIT has been shown to restore the allergen immune tolerance, can modify both the early and late-onset allergen-specific airway hyperreactivity, helps to achieve disease control/remission and prevents new sensitisations. Recent real life data on long-term effectiveness of house dust mite (HDM) AIT in a large group of patients with HDM-driven asthma further underscored its unique therapeutic potential as well as confirmed previous data with pollen AIT. More widespread use of this causal treatment in select patient populations should further move this promising therapeutic field. In this mini-review, we discuss updates on new insights based on real world patient data.</p>}},
  author       = {{Diamant, Zuzana and van Maaren, Maurits and Muraro, Antonella and Jesenak, Milos and Striz, Ilja}},
  issn         = {{0954-6111}},
  keywords     = {{Allergen immunotherapy; Asthma; Clinical effectiveness; Disease modification; Disease remission; Mechanisms; Prevention}},
  language     = {{eng}},
  month        = {{04}},
  publisher    = {{Elsevier}},
  series       = {{Respiratory Medicine}},
  title        = {{Allergen immunotherapy for allergic asthma : The future seems bright}},
  url          = {{http://dx.doi.org/10.1016/j.rmed.2023.107125}},
  doi          = {{10.1016/j.rmed.2023.107125}},
  volume       = {{210}},
  year         = {{2023}},
}